Skip to main content
RGEN
NASDAQ Life Sciences

Shareholders Re-elect Directors, Approve Exec Pay Amidst Notable Dissent

Analysis by Arik Shkolnikov
Sentiment info
Neutral
Importance info
7
Price
$103.38
Mkt Cap
$5.831B
52W Low
$100.99
52W High
$175.77
Market data snapshot near publication time

summarizeSummary

Repligen shareholders re-elected all nine director nominees and approved executive compensation, but several directors faced significant 'against' votes, indicating notable shareholder dissent.


check_boxKey Events

  • All Directors Re-elected

    All nine director nominees were re-elected to the Board of Directors at the 2026 Annual Meeting of Stockholders.

  • Significant Dissent for Key Directors

    Three directors, Glenn P. Muir, Carrie Eglinton Manner, and Karen A. Dawes, received 'Against' votes ranging from 17.6% to 25.6% of votes cast (excluding broker non-votes), indicating notable shareholder dissatisfaction.

  • Executive Compensation Approved

    The non-binding advisory vote to approve the compensation of named executive officers passed with 97.1% 'For' votes (excluding broker non-votes).

  • Auditor Ratified

    Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.


auto_awesomeAnalysis

While all director nominees were re-elected and executive compensation was approved, the significant 'Against' votes for several directors, particularly Glenn P. Muir (25.6% dissent), Carrie Eglinton Manner (19.0% dissent), and Karen A. Dawes (17.6% dissent), are notable. This dissent follows the company's recent proxy battle where it rebutted negative recommendations from Institutional Shareholder Services (ISS) and comes amidst ongoing disclosures of material weaknesses in internal controls. The level of shareholder dissatisfaction with specific board members could signal governance concerns, especially as the company trades near its 52-week low.

At the time of this filing, RGEN was trading at $103.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $100.99 to $175.77. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed RGEN - Latest Insights

RGEN
May 15, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
RGEN
May 06, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
RGEN
May 05, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
RGEN
May 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
RGEN
Apr 27, 2026, 4:03 PM EDT
Filing Type: DEFA14A
Importance Score:
8
RGEN
Apr 02, 2026, 4:13 PM EDT
Filing Type: DEF 14A
Importance Score:
7
RGEN
Feb 26, 2026, 4:03 PM EST
Filing Type: 10-K
Importance Score:
8
RGEN
Feb 24, 2026, 7:33 AM EST
Filing Type: 8-K
Importance Score:
7